All In Biotech

Drug Trial Radar · NCT05289557

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

A Multicenter Trial of the Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

274

Planned (sponsor's estimate)

Start

May 1, 2022

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Duchesnay Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12 to 17 years with placebo.

Conditions

  • Morning Sickness

Interventions

  • BonjestaDrug

    Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.

  • PlaceboDrug

    Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nausea and Vomiting of Pregnancy Severity from Baseline to Day 15Time frame: Day 1-Day 15

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Velvet Clinical Research

    Burbank, California

  • Vital Pharma Research

    Hialeah, Florida

  • New Horizon Research Center

    Miami, Florida

  • Emerald Coast OB/GYN Clinical Research

    Panama City, Florida

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Unified Women's Clinical Research

    Winston-Salem, North Carolina

  • Clinovacare Medical Research Center

    West Columbia, South Carolina

  • Maximos OBGYN

    League City, Texas

  • Axon Clinical Research

    Mesquite, Texas

  • Advances in Health

    Pearland, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.